Immunochemical assays for human amylase isoenzymes are disclosed. These assays utilize monoclonal antibodies which are produced from hybridoma cell lines and are specific for human salivary amylase and ovarian tumor amylase but not human pancreatic amylase. The assays involve reacting this monoclonal antibody with the unknown sample for the purpose of studying quantitatively and qualitatively the amylase isoenzymes present. The results from such assays are useful in the diagnosis of disease or ruling out disease. Antibody producing hybridoma cell lines and their production are described.

University of Virginia Alumni Patents Foundation

Immunochemical assays for human amylase isoenzymes and related monoclonal antibodies, hydridoma cell lines and production thereof

The invention is directed to a pharmaceutical preparation with a modulatory effect on malignant tumors, which contains a combination of protease proenzymes and amylases in a ratio between 1:100 and 100:1 in enzymatic activity units, and a protease inhibitor. The invention is also directed to use of such a preparation to modulate the effects of malignant tumors in humans and animals.

Pharmaceutical composition containing an isolated protease proenzyme, amylase, and aprotinin

A liniment composition for reversing or retarding the growth of cancerous skin tumors comprising primarily, pancreatin, pepsin, betaine HCL, emulsified vitamin A, and zinc, pancrelipase, fenugreek, papain, amylase and ox bile extract, with optional trace amounts of other ingredients.

Natural liniment for treatment of skin cancers

A gene expression system is used to produce heterologous biologically active proteins, in particular bioactive granulocyte macrophage colony stimulating factor ("GM-CSF"), secreted from a host selected from the Streptomyces genera. The gene expression system includes a regulatory nucleotide sequence linked to a second nucleotide sequence encoding the heterologous protein. The regulatory sequence, encodes a peptide which directs the secretion of the heterologous protein in bioactive form from a host selected from the Streptomyces genera. The regulatory sequence includes a signal sequence and a promoter sequence. The second nucleotide sequence, which encodes GM-CSF or a biologically active derivative of GM-CSF, may be either natural or synthetic. In particular, the invention relates to an expression system for secreting bioactive, non-glycosylated, oxidized, therapeutically useful GM-CSF from a host selected from the Streptomyces genera.Also disclosed are similar constructs for expression of interleukin 3 (IL-3), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF.alpha.), human stem cell factor (SCF), interleukin 7 (IL-7), erythropoietin (EPO) and interleukin 2 (IL-2). Novel signal peptides of these constructs include hybrids of the signal peptides of Streptomyces griseus protease B and Escherichia coli omp A, hybrids of Streptomyces griseus protease B and Streptomyces limosus .alpha.-amylase signal peptide.

Cangene Corporation

Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces

amylase/syöpä

Immunochemical assays for human amylase isoenzymes and related monoclonal antibodies, hydridoma cell lines and production thereof

Pharmaceutical composition containing an isolated protease proenzyme, amylase, and aprotinin

Natural liniment for treatment of skin cancers

Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces

Täydellisin lääketieteellinen tietokanta tieteen tukemana